Showing results (491-500 of 652) with videos related to

Sort By:
Pageof 66
The New England Journal of Medicine|November 4, 2005
Natalizumab induction and maintenance therapy for Crohn's diseaseWilliam J Sandborn, Jean Frédéric Colombel, Roberts Enns, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 30, 2011
Increased serum Dickkopf-1 levels in drug-abusing psychotic patientsDaniele Serata, Giorgio D Kotzalidis, Barbara Riozzi, et al.
Gastroenterology|May 9, 2007
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE TrialStephan R Targan, Brian G Feagan, Richard N Fedorak, et al.
Nature Communications|March 1, 2016
Layer-dependent quantum cooperation of electron and hole states in the anomalous semimetal WTe2Pranab Kumar Das, D Di Sante, I Vobornik, et al.
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
Journal of Crohn'S & Colitis|May 12, 2025
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitisGeert D'Haens, Silvio Danese, Remo Panaccione, et al.
Inflammatory Bowel Diseases|September 19, 2025
Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and ChallengesVipul Jairath, Shashi Adsul, Mariangela Allocca, et al.
ACS Nano|December 15, 2015
Magnetically Hard Fe3Se4 Embedded in Bi2Se3 Topological Insulator Thin Films Grown by Molecular Beam EpitaxyHugo Menezes do Nascimento Vasconcelos, Mahmoud Eddrief, Yunlin Zheng, et al.
The American Journal of Gastroenterology|December 29, 2022
REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort StudyChristopher Ma, Remo Panaccione, Yasi Xiao, et al.
The Lancet. Gastroenterology & Hepatology|May 10, 2025
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension studyRemo Panaccione, Séverine Vermeire, Silvio Danese, et al.
Pageof 66